Bone mineral metabolism changes in epileptic children receiving valproic acid

Basit Öğe Kaydı
dc.authoridTutunculer, Filiz/0000-0003-3710-288X
dc.contributor.authorÖner, N
dc.contributor.authorKaya, M
dc.contributor.authorKarasalihoglu, S
dc.contributor.authorKaraca, H
dc.contributor.authorÇeltik, C
dc.contributor.authorTütüncüler, F
dc.date.accessioned2024-06-12T10:54:56Z
dc.date.available2024-06-12T10:54:56Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: The aim of this study was to evaluate bone mineral density (BMD) in epileptic children receiving valproic acid (VPA) and to determine differences between osteopenic and non-osteopenic children. Methods: Thirty-three epileptic children, receiving VPA for at least 6 months, were compared with 33 healthy children for BMD. BMD was measured by dual-energy X-ray absorptiometry at lumbar vertebrae, femoral neck and greater trochanter. Serum calcium, phosphorus, alkaline phosphates, osteocalcin and VPA levels were also determined. Results: Patient's osteocalcin levels were significantly higher (P = 0.02) and femur and trochanter BMD values were significantly lower (P = 0.04 and P = 0.03, respectively). Duration of VPA therapy was significantly longer and doses of VPA were significantly higher in seven osteopenic patients compared with 26 non-osteopenic patients. Osteopenic patients (4.6 +/- 2.4 years) were younger than non-osteopenic patients (7.8 +/- 3.2 years) (P = 0.01). Conclusion: Long-term and high dose VPA therapy may cause osteopenia, primarily in younger epileptic children. These patients should be followed closely by BMD measurements.en_US
dc.identifier.doi10.1111/j.1440-1754.2004.00431.x
dc.identifier.endpage473en_US
dc.identifier.issn1034-4810
dc.identifier.issn1440-1754
dc.identifier.issue8en_US
dc.identifier.pmid15265190en_US
dc.identifier.scopus2-s2.0-4043131697en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage470en_US
dc.identifier.urihttps://doi.org/10.1111/j.1440-1754.2004.00431.x
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19236
dc.identifier.volume40en_US
dc.identifier.wosWOS:000222682300012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal Of Paediatrics And Child Healthen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBone Mineral Densityen_US
dc.subjectDual-Energy X-Ray Absorptiometryen_US
dc.subjectOsteocalcinen_US
dc.subjectValproic Aciden_US
dc.subjectTerm Anticonvulsant Therapyen_US
dc.subjectX-Ray Absorptiometryen_US
dc.subjectAntiepileptic Drugsen_US
dc.subjectCalcium-Metabolismen_US
dc.subjectDensityen_US
dc.subjectCarbamazepineen_US
dc.titleBone mineral metabolism changes in epileptic children receiving valproic aciden_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu